| In multiple myeloma, t (4; 14)(p16; q32) is an adverse prognostic factor irrespective of FGFR3 expression JJ Keats, T Reiman, CA Maxwell, BJ Taylor, LM Larratt, MJ Mant, ... Blood, The Journal of the American Society of Hematology 101 (4), 1520-1529, 2003 | 511 | 2003 |
| Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition LR Ferguson, H Chen, AR Collins, M Connell, G Damia, S Dasgupta, ... Seminars in cancer biology 35, S5-S24, 2015 | 383 | 2015 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 318 | 2015 |
| Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? CA Maxwell, J McCarthy, E Turley Journal of cell science 121 (7), 925-932, 2008 | 303 | 2008 |
| RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability CA Maxwell, JJ Keats, M Crainie, X Sun, T Yen, E Shibuya, M Hendzel, ... Molecular biology of the cell 14 (6), 2262-2276, 2003 | 251 | 2003 |
| Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer S Adamia, CA Maxwell, LM Pilarski Current Drug Targets-Cardiovascular & Hematological Disorders 5 (1), 3-14, 2005 | 222 | 2005 |
| Overexpression of transcripts originating from the MMSET locus characterizes all t (4; 14)(p16; q32)-positive multiple myeloma patients JJ Keats, CA Maxwell, BJ Taylor, MJ Hendzel, M Chesi, PL Bergsagel, ... Blood 105 (10), 4060-4069, 2005 | 208 | 2005 |
| Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity CA Maxwell, JJ Keats, AR Belch, LM Pilarski, T Reiman Cancer research 65 (3), 850-860, 2005 | 166 | 2005 |
| Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications CS Mitsiades, NS Mitsiades, RT Bronson, D Chauhan, N Munshi, ... Cancer research 63 (20), 6689-6696, 2003 | 146 | 2003 |
| Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer CA Maxwell, J Benítez, L Gómez-Baldó, A Osorio, N Bonifaci, ... PLoS biology 9 (11), e1001199, 2011 | 137 | 2011 |
| RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma CA Maxwell, E Rasmussen, F Zhan, JJ Keats, S Adamia, E Strachan, ... Blood 104 (4), 1151-1158, 2004 | 125 | 2004 |
| Targeted and nontargeted effects of ionizing radiation that impact genomic instability CA Maxwell, MC Fleisch, SV Costes, AC Erickson, A Boissière, R Gupta, ... Cancer research 68 (20), 8304-8311, 2008 | 111 | 2008 |
| Targeting aurora kinases as therapy in multiple myeloma Y Shi, T Reiman, W Li, CA Maxwell, S Sen, L Pilarski, TR Daniels, ... Blood 109 (9), 3915-3921, 2007 | 93 | 2007 |
| Hyaluronan mediated motility receptor (HMMR) encodes an evolutionarily conserved homeostasis, mitosis, and meiosis regulator rather than a hyaluronan receptor Z He, L Mei, M Connell, CA Maxwell Cells 9 (4), 819, 2020 | 87 | 2020 |
| The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs MC Fleisch, CA Maxwell, MH Barcellos-Hoff Endocrine-related cancer 13 (2), 379-400, 2006 | 80 | 2006 |
| Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers I Blanco, K Kuchenbaecker, D Cuadras, X Wang, D Barrowdale, ... PLoS One 10 (4), e0120020, 2015 | 79 | 2015 |
| The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma RP Evans, C Naber, T Steffler, T Checkland, CA Maxwell, JJ Keats, ... British journal of haematology 140 (3), 295-302, 2008 | 75 | 2008 |
| Geometric approach to segmentation and protein localization in cell culture assays S Raman, CA Maxwell, MH Barcellos‐Hoff, B Parvin Journal of microscopy 225 (1), 22-30, 2007 | 69 | 2007 |
| YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification AH Davies, I Barrett, MR Pambid, K Hu, AL Stratford, S Freeman, ... Oncogene 30 (34), 3649-3660, 2011 | 60 | 2011 |
| Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells R Evans, C Naber, T Steffler, T Checkland, J Keats, C Maxwell, T Perry, ... Leukemia & lymphoma 49 (3), 559-569, 2008 | 59 | 2008 |
